Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

47.99 -0.36 (-0.75%)
Streaming Delayed Price Updated: 11:16 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
31 32 Next >
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Was This $3 Billion Deal a Wise Move for Sanofi?
The French drugmaker appears to have meaningfully improved its portfolio with the acquisition. 
Via The Motley Fool
3 Biotech Stocks to Avoid Like the Plague
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs. 
Via InvestorPlace
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
Via Benzinga
2 Bear Market Defying Stocks to Buy in May
These stocks still have plenty of market-beating years ahead. 
Via The Motley Fool
Peering Into Sanofi's Recent Short Interest
Via Benzinga
Sanofi (SNY) Q1 2023 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)  
Via Benzinga
Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing
CEOs of Eli Lilly And Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and PBM e 
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have  
Via Benzinga
Earnings Outlook For Sanofi
Via Benzinga
Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Sanofi (NASDAQ: SNY) Climbs to New 52-Week High
Via Investor Brand Network
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies. 
Via Investor's Business Daily
What Wall Street Is Saying About Disney Ahead Of Earnings
Disney set to report amid fights with writers and DeSantis. 
Via Talk Markets
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
7 Blue-Chip Stocks to Buy in May 2023
While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy. 
Via InvestorPlace
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating  
Via Benzinga
7 Stock Upgrades and Downgrades Alerts You Cannot Ignore
Analyst stock upgrades and downgrades caught the market's attention in the last week and putting investors on notice for buys and sells. 
Via InvestorPlace
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Benzinga 
Via Benzinga
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public... 
Via Benzinga
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently... 
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.